1
|
Griffiths CD, Karanicolas P, Gallinger S, Wei AD, Francescutti V, Serrano PE. Health-Related Quality of Life Following Simultaneous Resection for Synchronous Colorectal Cancer Liver Metastases. Ann Surg Oncol 2023; 30:1331-1338. [PMID: 36350458 PMCID: PMC11005481 DOI: 10.1245/s10434-022-12696-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Accepted: 10/04/2022] [Indexed: 11/10/2022]
Abstract
INTRODUCTION Up to 25% of colorectal cancer patients present with synchronous liver metastases that can be treated with two operations or a single 'simultaneous' operation. Morbidity and mortality appear similar between approaches, however changes in health-related quality-of-life following simultaneous resection are not well reported. METHODS A prospective, feasibility trial for simultaneous resection of synchronous colorectal liver metastases was conducted. Patients completed the European Organization for Research and Treatment of Cancer QLQ-C30 and LMC21 at baseline (preoperatively), and 4 and 12 weeks postoperatively. Week 4 and 12 scores were compared with baseline using t-tests. Minimally important clinical differences were considered as a 10-point difference from baseline. RESULTS C30 and QLQ-LMC21 were completed at baseline, 4 weeks, and 12 weeks by 39 (95%), 35 (85%) and 34 (83%) patients, and 39 (95%), 33 (80%) and 33 (80%) patients, respectively; 79% and 75% had at least one MICD according to QLQ-C30 at 4 and 12 weeks. At 4 weeks, physical functioning (mean difference (MD) - 11.9%, p = 0.002), role functioning (MD - 23.6, p = 0.007), and pain (MD + 19.7, p = 0.017) had significant worsening from baseline. At 12 weeks postoperatively, role functioning (MD - 19.7, p = 0.011) and fatigue (MD + 14.3, p = 0.03) were the only domains that remained significantly worse. By 12 weeks, pain and physical functioning had returned to baseline. There were no major demographic differences among those with and without an MICD at 12 weeks. CONCLUSIONS Simultaneous resection of colorectal liver metastases led to clinically significant worsening fatigue and role functioning that persisted at 12 weeks post-surgery.
Collapse
Affiliation(s)
- C D Griffiths
- Department of Surgery, McMaster University, Hamilton, ON, Canada
| | - P Karanicolas
- Department of Surgery, University of Toronto, Toronto, ON, Canada
- Division of General Surgery, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - S Gallinger
- Department of Surgery, University of Toronto, Toronto, ON, Canada
- Department of Surgery, University Health Network, Toronto, ON, Canada
| | - A D Wei
- Department of Surgery, Memorial Sloan Kettering Cancer Centre, New York, NY, USA
| | - V Francescutti
- Department of Surgery, McMaster University, Hamilton, ON, Canada
| | - P E Serrano
- Department of Surgery, McMaster University, Hamilton, ON, Canada.
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
- Juravinski Hospital, Hamilton, ON, Canada.
| |
Collapse
|
2
|
Kazi M, Patkar S, Patel P, Kunte A, Desouza A, Saklani A, Goel M. Simultaneous resection of synchronous colorectal liver metastasis: Feasibility and development of a prediction model. Ann Hepatobiliary Pancreat Surg 2023; 27:40-48. [PMID: 36168272 PMCID: PMC9947373 DOI: 10.14701/ahbps.22-043] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 07/13/2022] [Accepted: 07/21/2022] [Indexed: 11/17/2022] Open
Abstract
BACKGROUNDS/AIMS Timing of resection for synchronous colorectal liver metastasis (CRLM) has been debated for decades. The aim of the present study was to assess the feasibility of simultaneous resection of CRLM in terms of major complications and develop a prediction model for safe resections. METHODS A retrospective single-center study of synchronous, resectable CRLM, operated between 2013 and 2021 was conducted. Upper limit of 95% confidence interval (CI) of major complications (≥ grade IIIA) was set at 40% as the safety threshold. Logistic regression was used to determine predictors of morbidity. Prediction model was internally validated by bootstrap estimates, Harrell's C-index, and correlation of predicted and observed estimates. RESULTS Ninety-two patients were operated. Of them, 41.3% had rectal cancers. Major hepatectomy (≥ 4 segments) was performed for 25 patients (27.2%). Major complications occurred in 20 patients (21.7%, 95% CI: 13.8%-31.5%). Predictors of complications were the presence of comorbidities and major hepatectomy (area under the ROC curve: 0.692). Unacceptable level of morbidity (≥ 40%) was encountered in patients with comorbidities who underwent major hepatectomy. CONCLUSIONS Simultaneous bowel and CRLM resection appear to be safe. However, caution should be exercised when combining major liver resections with bowel resection in patients with comorbid conditions.
Collapse
Affiliation(s)
- Mufaddal Kazi
- Division of Gastrointestinal and Hepatopancreaticobiliary Surgery, Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| | - Shraddha Patkar
- Division of Gastrointestinal and Hepatopancreaticobiliary Surgery, Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| | - Prerak Patel
- Division of Gastrointestinal and Hepatopancreaticobiliary Surgery, Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| | - Aditya Kunte
- Division of Gastrointestinal and Hepatopancreaticobiliary Surgery, Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| | - Ashwin Desouza
- Division of Gastrointestinal and Hepatopancreaticobiliary Surgery, Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| | - Avanish Saklani
- Division of Gastrointestinal and Hepatopancreaticobiliary Surgery, Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| | - Mahesh Goel
- Division of Gastrointestinal and Hepatopancreaticobiliary Surgery, Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| |
Collapse
|
3
|
Serrano PE, Griffiths CD, Fabbro M, Jibrael S, Levine M, Bhandari M, Parpia S, Simunovic M. Use of population-based electronic databases for the identification of patients with synchronous colorectal cancer and liver metastases potentially eligible for a surgical trial. Can J Surg 2023; 66:E52-E58. [PMID: 36731910 PMCID: PMC9904807 DOI: 10.1503/cjs.020421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/13/2022] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Some population-based recruitment methods, such as registries and databases, have been used to increase enrolment in clinical trials by identifying eligible participants based on baseline characteristics; however; these methods have not been tested in surgical trials, in which accrual occurs before surgery. We evaluated the use of population-based electronic databases to identify patients who potentially could be accrued to the Simultaneous Resection of Colorectal Cancer with Synchronous Liver Metastases (RESECT) trial and compared it to the traditional methods used to accrue patients (e.g., multidisciplinary rounds, letters to community surgeons) for that same trial during the same period. METHODS An electronic database (ePath) was interrogated every 2 weeks for patients diagnosed with colorectal cancer from Feb. 1, 2017, to Mar. 30, 2019. A radiologic image database (OneView) was reviewed to identify those with liver metastases (level 1 screening). Reports were interrogated to identify potentially eligible patients for the RESECT trial (level 2 screening). A hepatobiliary surgeon reviewed radiology images to identify eligible patients for the trial (level 3 screening). The primary outcome was patient eligibility for the ongoing RESECT trial. RESULTS The population-based method identified 90 (11.2%) of 803 patients diagnosed with colorectal cancer over the study period. Among the 90 patients, level 2 screening identified 60 (67%) potentially eligible patients for the RESECT trial. Of the 90 patients, 18 (20%) were eligible after radiographic image review (level 3 screening). Traditional accrual methods identified 38 patients with liver metastases, 27 (71%) of whom were identified as potentially eligible on level 2 screening, and 14 (37%) of whom were deemed to be eligible on level 3 screening. Twenty-six patients were identified by both methods. Twelve patients were identified by population-based methods alone, and 8 patients by traditional methods alone. Six eligible patients were identified by both methods. Baseline characteristics were similar between the 2 groups. CONCLUSION A population-based electronic database method of patient accrual was able to identify eligible participants for the RESECT trial. However, optimal accrual likely requires the use of traditional methods as well.
Collapse
Affiliation(s)
- Pablo E Serrano
- From the Department of Surgery, McMaster University, Hamilton, Ont. (Serrano, Griffiths, Jibrael, Bhandari, Simunovic); the Ontario Clinical Oncology Group, Hamilton, Ont. (Serrano, Griffiths, Levine, Parpia); the Trinity College Dublin, Dublin, Ireland (Fabbro); and the Department of Oncology, McMaster University, Hamilton, Ont. (Levine, Parpia, Simunovic)
| | - Christopher D Griffiths
- From the Department of Surgery, McMaster University, Hamilton, Ont. (Serrano, Griffiths, Jibrael, Bhandari, Simunovic); the Ontario Clinical Oncology Group, Hamilton, Ont. (Serrano, Griffiths, Levine, Parpia); the Trinity College Dublin, Dublin, Ireland (Fabbro); and the Department of Oncology, McMaster University, Hamilton, Ont. (Levine, Parpia, Simunovic)
| | - Matthew Fabbro
- From the Department of Surgery, McMaster University, Hamilton, Ont. (Serrano, Griffiths, Jibrael, Bhandari, Simunovic); the Ontario Clinical Oncology Group, Hamilton, Ont. (Serrano, Griffiths, Levine, Parpia); the Trinity College Dublin, Dublin, Ireland (Fabbro); and the Department of Oncology, McMaster University, Hamilton, Ont. (Levine, Parpia, Simunovic)
| | - Sinan Jibrael
- From the Department of Surgery, McMaster University, Hamilton, Ont. (Serrano, Griffiths, Jibrael, Bhandari, Simunovic); the Ontario Clinical Oncology Group, Hamilton, Ont. (Serrano, Griffiths, Levine, Parpia); the Trinity College Dublin, Dublin, Ireland (Fabbro); and the Department of Oncology, McMaster University, Hamilton, Ont. (Levine, Parpia, Simunovic)
| | - Mark Levine
- From the Department of Surgery, McMaster University, Hamilton, Ont. (Serrano, Griffiths, Jibrael, Bhandari, Simunovic); the Ontario Clinical Oncology Group, Hamilton, Ont. (Serrano, Griffiths, Levine, Parpia); the Trinity College Dublin, Dublin, Ireland (Fabbro); and the Department of Oncology, McMaster University, Hamilton, Ont. (Levine, Parpia, Simunovic)
| | - Mohit Bhandari
- From the Department of Surgery, McMaster University, Hamilton, Ont. (Serrano, Griffiths, Jibrael, Bhandari, Simunovic); the Ontario Clinical Oncology Group, Hamilton, Ont. (Serrano, Griffiths, Levine, Parpia); the Trinity College Dublin, Dublin, Ireland (Fabbro); and the Department of Oncology, McMaster University, Hamilton, Ont. (Levine, Parpia, Simunovic)
| | - Sameer Parpia
- From the Department of Surgery, McMaster University, Hamilton, Ont. (Serrano, Griffiths, Jibrael, Bhandari, Simunovic); the Ontario Clinical Oncology Group, Hamilton, Ont. (Serrano, Griffiths, Levine, Parpia); the Trinity College Dublin, Dublin, Ireland (Fabbro); and the Department of Oncology, McMaster University, Hamilton, Ont. (Levine, Parpia, Simunovic)
| | - Marko Simunovic
- From the Department of Surgery, McMaster University, Hamilton, Ont. (Serrano, Griffiths, Jibrael, Bhandari, Simunovic); the Ontario Clinical Oncology Group, Hamilton, Ont. (Serrano, Griffiths, Levine, Parpia); the Trinity College Dublin, Dublin, Ireland (Fabbro); and the Department of Oncology, McMaster University, Hamilton, Ont. (Levine, Parpia, Simunovic)
| |
Collapse
|
4
|
Alexandrescu ST, Zarnescu NO, Diaconescu AS, Tomescu D, Droc G, Hrehoret D, Brasoveanu V, Popescu I. The Impact of Postoperative Complications on Survival after Simultaneous Resection of Colorectal Cancer and Liver Metastases. Healthcare (Basel) 2022; 10:healthcare10081573. [PMID: 36011230 PMCID: PMC9408276 DOI: 10.3390/healthcare10081573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Revised: 08/17/2022] [Accepted: 08/18/2022] [Indexed: 11/24/2022] Open
Abstract
Background: The aim of this study was to investigate the impact of postoperative complications on the long-term outcomes of patients who had undergone simultaneous resection (SR) of colorectal cancer and synchronous liver metastases (SCLMs). Methods: We conducted a single-institution survival cohort study in patients with SR, collecting clinical, pathological, and postoperative complication data. The impact of these variables on overall survival (OS) and disease-free survival (DFS) was compared by log rank test. Multivariate Cox regression analysis identified independent prognostic factors. Results: Out of 243 patients, 122 (50.2%) developed postoperative complications: 54 (22.2%) major complications (Clavien–Dindo grade III–V), 86 (35.3%) septic complications, 59 (24.2%) hepatic complications. Median comprehensive complication index (CCI) was 8.70. Twelve (4.9%) patients died postoperatively. The 3- and 5-year OS and DFS rates were 60.7%, 39.5% and 28%, 21.5%, respectively. Neither overall postoperative complications nor major and septic complications or CCI had a significant impact on OS or DFS. Multivariate analysis identified the N2 stage as an independent prognostic of poor OS, while N2 stage and four or more SCLMs were independent predictors for poor DFS. Conclusion: N2 stage and four or more SCLMs impacted OS and/or DFS, while CCI, presence, type, or grade of postoperative complications had no significant impact on long-term outcomes.
Collapse
Affiliation(s)
- Sorin Tiberiu Alexandrescu
- Department of General Surgery, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Department of Surgery, Center for Digestive Disease and Liver Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Narcis Octavian Zarnescu
- Department of General Surgery, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Second Department of Surgery, University Emergency Hospital Bucharest, 050098 Bucharest, Romania
- Correspondence: ; Tel.: +40-723-592-483
| | - Andrei Sebastian Diaconescu
- Department of General Surgery, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Department of Surgery, Center for Digestive Disease and Liver Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Dana Tomescu
- Department of General Surgery, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- 3rd Department of Anesthesia and Intensive Care, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Gabriela Droc
- Department of General Surgery, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- 1st Department of Anesthesia and Intensive Care, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Doina Hrehoret
- Department of Surgery, Center for Digestive Disease and Liver Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Vladislav Brasoveanu
- Department of Surgery, Center for Digestive Disease and Liver Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Faculty of Medicine, « Titu Maiorescu » University, 040441 Bucharest, Romania
| | - Irinel Popescu
- Department of Surgery, Center for Digestive Disease and Liver Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Faculty of Medicine, « Titu Maiorescu » University, 040441 Bucharest, Romania
| |
Collapse
|